SRX3207 |
カタログ番号GC62456 |
SRX3207 は、Syk と PI3Kα の IC50 値がそれぞれ 10.7 nM と 861 nM である、経口で活性なクラス初のデュアル Syk/PI3K 阻害剤です。 SRX3207 は、腫瘍の免疫抑制を軽減します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2254693-15-5
Sample solution is provided at 25 µL, 10mM.
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2].
SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1].SRX3207 has sufficient solubility in water (43 μmol/L)[1].
SRX3207 (10 mg/kg, orally) increases antitumor immune response[1].
[1]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
[2]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *